Cover Image
市場調查報告書

幹細胞的技術與用途 2016-2026年:全球產業及市場展望

Stem Cell Technologies and Applications Market Report 2016-2026: Hype vs Reality for That Transformative Technology with Vast R&D Pipeline and Expanding Use of HSCT and Cord Blood Banking

出版商 Visiongain Ltd 商品編碼 203833
出版日期 內容資訊 英文 292 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
幹細胞的技術與用途 2016-2026年:全球產業及市場展望 Stem Cell Technologies and Applications Market Report 2016-2026: Hype vs Reality for That Transformative Technology with Vast R&D Pipeline and Expanding Use of HSCT and Cord Blood Banking
出版日期: 2015年12月02日 內容資訊: 英文 292 Pages
簡介

2016年之後,幹細胞的技術、服務,及產品,有著發展、投資及銷售額擴大的大幅潛力。幹細胞的市場預計從2015年到2026年達成2位數收益成長,2019年時的市場整體規模達到158億美元。

本報告提供幹細胞的技術與用途的發展趨勢的相關調查、幹細胞研究的發展過程與現狀、各疾病種類的市場規模的變化與預測、幹細胞的非治療用途的發展、主要的幹細胞治療藥概要、治療方法及藥物的開發情形、推動市場成長的要素與阻礙要素分析、專家的採訪等彙整資料。

第1章 報告概要

第2章 幹細胞的技術與用途:簡介

  • 幹細胞為何? 特徵定義
  • 幹細胞研究的時間軸
  • ES細胞變得重要
  • 幹細胞的效能的分類
  • 幹細胞的主要類型和特徵
  • iPS細胞:ES細胞有優點,可是沒有不合適的方面嗎?
  • 單性生殖幹細胞:科學背景
  • 自我移植 vs. 同種異體幹細胞
  • 臨床試驗的階段
  • 本報告的調查範圍

第3章 國際性發展及幹細胞的法規環境

  • 美國的法規環境
  • 歐洲的法規環境
  • 日本的法規環境
  • 韓國的法規環境
  • 中國的法規環境
  • 以色列的法規環境
  • 印度的法規環境

第4章 幹細胞的技術與用途:全球市場

  • 幹細胞的治療用途 vs. 非治療用途
  • 全球市場的地區分析
  • 市場區隔
  • 幹細胞的技術與用途:市場預測
  • 幹細胞的技術與用途:各種類的預測
  • 各種類佔有率的變化預測
  • 幹細胞的技術與用途:市場促進因素&阻礙要素

第5章 由於幹細胞的癌症治療部門的預測

  • 幹細胞的癌症治療:概要與現狀
  • 幹細胞的癌症治療:市場預測
  • 造血幹細胞移植 (HSCT)
  • 術向產品:臍帶血幹細胞的認證
  • 幹細胞的癌症治療開發平台
  • 幹細胞的癌症治療:成長推動因素&阻礙要素

第6章 幹細胞的心血管疾病治療部門的預測

  • 幹細胞的心血管疾病治療:概要與現狀
  • 幹細胞的心血管疾病治療:市場預測
  • 全球醫藥品市場上中心的心血管疾病
  • 心血管疾病的幹細胞研究現況
  • 心臟的幹細胞難以說明的效果
  • 市售幹細胞的心臟疾病治療藥
  • 幹細胞的心臟疾病治療開發平台
  • 幹細胞的心臟疾病治療:成長推動因素&阻礙要素

第7章 幹細胞的中樞神經系統 (CNS) 疾病治療部門的預測

  • 幹細胞的中樞神經系統疾病治療:概要與現狀
  • 幹細胞的中樞神經系統疾病治療:市場預測
  • CNS疾病的幹細胞調查現況
  • 特定的CNS疾病上的進步
  • 如果幹細胞的可能性轉能換為治療,幹細胞開發者將打開數十億美元的市場
  • 幹細胞的中樞神經系治療的開發平台
  • 幹細胞的中樞神經系治療:成長推動因素&阻礙要素

第8章 幹細胞的其他疾病治療部門的預測

  • 幹細胞的其他疾病治療:概要與現狀
  • 幹細胞的其他疾病治療:市場預測
  • 其他疾病的幹細胞治療
  • 幹細胞的其他疾病治療:開發平台的檢討
  • 基因改造幹細胞治療

第9章 幹細胞的非治療用途部門的預測

  • 幹細胞的非治療的用途:概要與現狀
  • 幹細胞的非治療的用途:市場預測
  • 幹細胞銀行:全球的需求增加
  • 幹細胞的供給和加工:iPS細胞是新推動因素
  • 幹細胞為基礎的化驗:前臨床篩檢的大幅可能性
  • 在研究、試劑、其他非治療領域的配合措施
  • 成長推動因素&阻礙要素

第10章 幹細胞技術、用途市場預測:定性分析

  • SWOT分析
  • 優勢
  • 弱點
  • 機會
  • 威脅
  • STEP分析
  • 社會要素
  • 技術性要素
  • 經濟要素
  • 政治要素

第11章 專家的採訪

第12章 總論

  • 幹細胞的技術與用途:新興市場
  • 目前主要區分與地區市場
  • 全球幹細胞技術、用途市場預測
  • 幹細胞技術、用途市場未來

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: PHA0080

Stem cells - discover revenue prospects and developments for cancer treatment, cardiovascular therapy, CNS uses, other therapies and non-therapeutic applications

What does the future hold for stem cells? What progress and sales are possible? Avoid struggles to gain that business data. Instead find the best places for expanding revenues, also understanding trends, technologies, therapies and opportunities.

Visiongain's new investigation gives you revenue forecasts to 2026 for the world stem cells market, submarkets and leading products. Avoid missing out. There see what is happening for those cell-based technologies and their uses, discovering the most lucrative applications.

See what gains are possible. Please read on, then, to explore that industry and discover what its future market could be worth.

Forecasts and other analyses showing opportunities in those cellular technologies

Besides revenue forecasting to 2026, our analyses show recent results, growth rates and market shares. There you find original analysis. Our work also explains research and development. You gain 68 tables, 41 charts and our interviews with five authorities.

Now make your searching for data on stem cells easier. Also save time and benefit your insight and authority. Our study's purpose is to benefit your research, analysis and decisions, helping you see where developments and money lie, staying ahead in knowledge.

The following sections show how visiongain's new investigation helps your work.

Prospects for the overall world market and segments - what is possible?

What are the secrets of that industry's progress? Along with our prediction of the overall world market value for stem cells, our study shows you individual revenue forecasting of five submarkets to 2026 at world level, with discussions:

  • Cancer treatment (oncology)
  • Cardiovascular therapy
  • CNS uses
  • Other therapies
  • Non-therapeutic applications.

Which segment will achieve highest sales? Which has fastest predicted growth? See how and why those commercial uses in healthcare will develop, prosper and gain in importance.

For developers, producers and sellers, assess how those tools, systems and applications earn money. Also gauge their potential success from 2016, finding the most lucrative applications.

Products - discover sales forecasting for leading therapies

Our study also shows you individual revenue predictions to 2026 for six top brands:

  • MSC-100-IV (Mesoblast)
  • Hearticellgram-AMI (Pharmicell)
  • CardioRel (Reliance Life Sciences)
  • Osteocel Plus (NuVasive)
  • Trinity Evolution and Elite (Orthofix)
  • CARTISTEM (MEDIPOST).

In our analyses you discover prospects for established and emerging technology and medicines. That market will expand through the approval and launch of many products from 2016.

Our study explains what the future holds, discussing issues to help your work.

Developments, challenges and opportunities affecting researchers, producers and users

Our investigation lets you assess trends, R&D and outlooks for stem cell technology. There you find discussions of forces, progress and potential:

  • Developments in the US, Japan, Europe, South Korea, China, India and Israel - regulations, progress, potentials, expertise, regional prominence and outlooks
  • Activities of Mesoblast, Pharmicell, NuVasive, Orthofix, Medipost and other organisations, private and public - explore prominent and rising competitors
  • Approvals of therapies and other products to expand and advance that industry
  • Treatments for orphan diseases and difficult-to-cure disorders
  • Regenerative medicine and uses in diabetes, liver repair, Crohn's disease, rheumatoid arthritis, eye disorders and other therapeutic applications.

Out study discusses other influences on that field, including these:

  • Haematopoietic stem cell transplantation (HSCT)
  • Embryonic stem cells (ESCs), induced pluripotent adult (IPSCs) and parthenogenetic cells
  • Uses for umbilical cord blood and related technologies, including cellular and blood banking
  • Agents for osteogenesis and treating autoimmune conditions
  • Applications in cell-based assays, diagnostics and drug development.

There you explore political, economic, social and technological questions, assessing advances and prospects. You also gain in regulatory insight. You investigate what helps and restrains stem cell developers, producers and marketers, seeing what they can achieve.

Discover in our report what the past, present and future hold for those cellular technologies.

Stem cells - what revenue could that overall world market earn in 2019?

From 2016 those technologies, services and products hold great potential for advances, investments and sales. Our work predicts the overall market for stem cells will reach $15.8bn in 2019, achieving double-digit revenue growth from 2015 to 2026.

Our report's author said: "Factors such as the increasing use of hematopoietic stem cell transplantation (HSCT), the launch of current pipeline therapies and the expanding use of cord blood bank services and cell-based assays will stimulate this market over the next ten years."

Prospects for those medical products, systems and tools are great. From 2015 there will arise many opportunities. Our work explains what is possible, helping you stay ahead in knowledge and influence.

Stem Cell Technologies and Applications Market Report 2016-2026 shows data and analysis you find nowhere else

In particular you gain these analyses to help your research, plans, decisions and presentations:

  • Overall world revenue to 2026 - see the results and sales potential of that industry
  • Five submarkets' revenues to 2026 - investigate segments at world level, finding the most promising and lucrative applications
  • Six product revenues to 2026 - discover sales predictions for top medical agents, seeing how they can succeed, including what helps and limits their performance
  • R&D on stem cells - investigate progress, finding technological, clinical and commercial outlooks, exploring expected products
  • Activities of established, rising and emerging companies - hear about firms' capabilities, portfolios, advances and prospects
  • Interviews with five organisations - explore views to benefit your work, helping you assess that sector, its participants and potential
  • Analysis of what stimulates and restrains that industry and market - gauge challenges and strengths, helping you compete, gain advantages and succeed.

You also receive our interviews with the Human Stem Cells Institute (HSCI), Apceth, MEDIPOST, Harvard Stem Cells Institute and the Stem Cell Program at Boston's Children's Hospital.

Potential for stem cells - discover now what is possible for those organisations

With our study you receive business intelligence found only in our work, discovering where money, progress and opportunities lie. That way you can benefit your influence and reputation for insight, staying ahead in knowledge. Gain information you find nowhere else.

With our new investigation you are less likely to miss opportunity or fall behind. There you explore trends, R&D and sales predications. Stay ahead by getting our report here now.

Visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Report Overview

  • 1.1. Global Stem Cell Technologies and Applications Market Overview
  • 1.2. Global Stem Cell Technologies and Applications Market Segmentation
  • 1.3. Why you Should Read This Report
  • 1.4. How this Report Delivers
  • 1.5. Key Questions Answered by This Report
  • 1.6. Who is Report for?
  • 1.7. Research and Analysis Methods
  • 1.8. Frequently Asked Questions (FAQ)
  • 1.9. Some Associated Reports
  • 1.10. About Visiongain

2. Introduction to Stem Cell Technologies and Applications

  • 2.1. What are Stem Cells? Defining Characteristics
  • 2.2. Timeline of Stem Cell Research
  • 2.3. Embryonic Stem Cells (ESCs) Enter the Picture
  • 2.4. Classifying Stem Cells by Potency
    • 2.4.1. Post Fertilisation and Germ Layers
  • 2.5. The Main Types of Stem Cells and Their Properties
  • 2.6. iPSCs: The Benefits of ESCs, but Without the Downsides?
    • 2.6.1. CIRM hPSC Repository Launches 300 iPSC Lines
  • 2.7. Parthenogenetic Stem Cells: Scientific Background
    • 2.7.1. Are they Ethical Alternatives to ESCs? What are the Commercial Applications?
  • 2.8. Autologous Versus Allogeneic Stem Cells
    • 2.8.1. Are Universal Stem Cell Products Possible?
  • 2.9. Phases of Clinical Trials
  • 2.10. Scope of this Report

3. International Developments and Stem Cell Regulatory Environments

  • 3.1. Regulatory Environment in the US
    • 3.1.1. Dynamic Biotechnology Sector and Liberal Stance on Patents
    • 3.1.2. Understanding ‘Homologous' Use
    • 3.1.3. Controversy Surrounding ESC Research
    • 3.1.4. NIH ESC Stem Cell Registry: Has Made Good Progress, but not Enough for its Critics
    • 3.1.5. CIRM Allocates Close to $2bn in Stem Cell Funding into Various Channels
    • 3.1.6. FDA vs Regenerative Sciences
    • 3.1.7. Are Stem Cells Clinics the ‘Wild West' of Medicine?
    • 3.1.8. Stem Cell Clinics Using Loopholes to Avoid Oversight?
    • 3.1.9. FDA Releases Three New Draft Guidances, but is it Doing Enough?
  • 3.2. Regulatory Environment in Europe
    • 3.2.1. Unified Overarching System of Regulation Across EU
    • 3.2.2. Difference Between EU Member States Regarding hESC Research
    • 3.2.3. European Court of Justice Performs an U-Turn and Clears Path Towards Stem Cell Patents
    • 3.2.4. The UK: A Leader in European Stem Cell Research
  • 3.3. Regulatory Environment in Japan
    • 3.3.1. Liberal Stance on hESC but with Excessive Bureaucracy?
    • 3.3.2. Japan: A Pioneer in iPSC Research, Although First In-Human Trial has been Suspended
    • 3.3.3. The STAP Cell Events: Excitement Dashed
      • 3.3.3.1 Riken Concludes Investigation
    • 3.3.4. Government Committed to Regenerative Medicines and iPSC Research
    • 3.3.5. Japan Becomes Very Attractive Market for Stem Cell Companies due to Favourable Regulatory Changes
  • 3.4. Regulatory Environment in South Korea
    • 3.4.1. Highs and Lows with Regard to hESC Research
    • 3.4.2. Regulators are Quick to Approve Therapies, Although this has Drawn Criticism
    • 3.4.3. Tracheal Transplant Patient Dies
  • 3.5. Chinese Regulatory Environment
    • 3.5.1. Liberal Regulation on Stem Cells and Very High Number of Stem Cell Clinical Trials Taking Place in the Country
    • 3.5.2. Stem Cell Medical Tourism Very Popular
    • 3.5.3. CFDA Releases New Stem Cell Draft Guidance
  • 3.6. Israeli Regulatory Environment: A Strong Presence in Stem Cell Research
  • 3.7. Indian Regulatory Environment: Emerging Stem Cell Industry - in Need of more Regulation?

4. Stem Cell Technologies and Applications: World Market 2015-2026

  • 4.1. Therapeutic Applications Versus Non-Therapeutic Applications of Stem Cells
  • 4.2. Regional Breakdown of the World Market
  • 4.3. Market Segmentation
  • 4.4. Stem Cell Technologies and Applications Market: Forecast 2015-2026
  • 4.5. Stem Cell Technologies and Applications Market: Forecast by Segment 2015-2026
  • 4.6. How Will Segmental Market Shares Change to 2026?
    • 4.6.1. Which Segments will Grow the Most?
  • 4.7. Stem Cell Technologies and Applications Market: Drivers and Restraints 2015-2026

5. Stem Cell Cancer Therapeutics Segment 2015-2026

  • 5.1. Stem Cell Cancer Therapeutics: Overview and Current Status
  • 5.2. Stem Cell Cancer Therapeutics: Market Forecast 2015-2026
  • 5.3. Haematopoietic Stem Cell Transplantation (HCST)
    • 5.3.1. An Established Treatment for Haematological Cancers
    • 5.3.2. Autologous HSCT: Dominant Form of HSCT
    • 5.3.3. Autologous Versus Allogeneic HSCT: Advantages and Disadvantages
    • 5.3.4. GvHD: The Major Issue for HSCT
    • 5.3.5. Strengths and Weaknesses of the Three Major Sources of HSCs
    • 5.3.6. What is Cord Blood?
      • 5.3.6.1. Cord Blood Use Rising in HSCT
    • 5.3.7. Number of HSCT Operations Performed Worldwide, Split by Autologous Versus Allogeneic HSCT, 2012-2014
      • 5.3.7.1. Numbers of HSCT Operations Performed in Europe, Split by Donor Type, 2003-2012
    • 5.3.8. HSCT Costs and Medicare Coverage
    • 5.3.9. The Indications which can be treated with HSCT: Haematological Malignancies are the Major Indications
    • 5.3.10. HSCT has the Potential to Address Multiple Cancers, which Represent a $20bn+ Market
  • 5.4. From Procedures to Products: Cord Blood Stem Cell Approvals
    • 5.4.1. Hemacord (New York Blood Center): The First FDA-Approved Cord Blood Product
      • 5.4.1.1. Hemacord Awarded Prix Galien ‘Best Biotechnology Product' Award
    • 5.4.2. HPC, Cord Blood (ClinImmune Labs / University of Colorado Blood Bank)
    • 5.4.3. Ducord (Duke University School of Medicine)
    • 5.4.4. Allocord (SSM Cardinal Glennon Children's Medical Center)
    • 5.4.5. HPC, Cord Blood BLA 125432 (LifeSouth Community Blood Centers)
  • 5.5. Stem Cell Cancer Therapeutics Pipeline
    • 5.5.1. Agenmestencel-T (Apceth)
    • 5.5.2. CLT-008 and CLT-009 (Cellerant Therapeutics): Company Receives $47.5m Grant from US Government
    • 5.5.3. ProHema (Fate Therapeutics)
      • 5.5.3.1. ProTmune: Company Planning to file IND in Second Half of 2015
    • 5.5.4. StemEx and NiCord (Gamida Cell)
      • 5.5.4.1. StemEx Shows Improved Survival at 100 Days - but FDA Wants Another Clinical Trial
      • 5.5.4.2. Copper Chelator Based Technology
      • 5.5.4.3. NiCord
      • 5.5.4.4. NiCord: Company Aiming for a “Paradigm Shift” in Treatment Practice, Receives Orphan Drug Designation
      • 5.5.4.5. NiCord: Gamida Cell Reaches Agreement on Phase 3 Design Outline with the FDA and EMA
      • 5.5.4.6. NAM Technology Platform
      • 5.5.4.7. Novartis Chooses Not to Buy Gamida Cell
    • 5.5.5. MSC-100-IV (Previously Known as Prochymal) and Unnamed MPC-Expanded Cord Blood Product (Mesoblast)
      • 5.5.5.1. MSC-100-IV: World's First Approved Stem Cell Drug Outside of South Korea
      • 5.5.5.2. MSC-100-IV: Culture Expanded and Able to Treat GvHD
      • 5.5.5.3. An Important Role to Play in the Future of HSCT
      • 5.5.5.4. Wins Approval in Japan, through Partner JCR Pharmaceuticals, and Phase 3 Trial will Support US BLA
      • 5.5.5.5. MSC-100-IV / Temcell HS Injection Revenue Forecast 2015-2026
      • 5.5.5.6. MPC-Expanded Cord Blood Product in a Phase 3 Trial for Haematological Malignancies
    • 5.5.6. HSC835 (Novartis)
      • 5.5.6.1. Novartis Enters Partnership Agreement with Regenerex to Develop Novel Cell-Based Therapies
      • 5.5.6.2. Collaborations with Intellia Therapeutics and Caribou for CRISPR and HSCs
    • 5.5.7. Ancillary Products for the HSCT Setting
    • 5.5.8. Targeting of Cancer Stem Cells (CSCs)
  • 5.6. Stem Cell Cancer Therapeutics: Drivers and Restraints 2015-2026

6. Stem Cell Cardiovascular Therapeutics Segment 2015-2026

  • 6.1. Stem Cell Cardiovascular Therapeutics: Overview and Current Status
  • 6.2. Stem Cell Cardiovascular Therapeutics: Market Forecast 2015-2026
  • 6.3. Cardiovascular Diseases Make up a Large part of the Global Pharmaceutical Market
    • 6.3.1. Stem Cell Treatments for Stroke: Touched Upon in This Chapter but mainly Covered under Central Nervous System Therapeutics
    • 6.3.2. Cardiovascular and Cerebrovascular Conditions are the World's Most Fatal Diseases
    • 6.3.3. AMI, CLI and Stroke: Major Ischaemic Disease Targets
  • 6.4. The State of Stem Cell Research for Cardiovascular Diseases
    • 6.4.1. Practical Advantages to Choosing the Heart as a Target for Stem Cell R&D
    • 6.4.2. Defining Cardiovascular Stem Cells: Scientific Context
  • 6.5. The Mysterious Effects of Stem Cells in the Heart
    • 6.5.1. MSCs in the Heart: Evidence to Support their Use, as well as Doubts over their Efficacy
    • 6.5.2. Cardiosphere-Derived Cells, hESC-Derived Cardiomyocytes and C-kit Cells
  • 6.6. Stem Cell Cardiovascular Therapeutics on the Market
    • 6.6.1. Hearticellgram-AMI (Pharmicell)
      • 6.6.1.1. One of the First Approved Cardiovascular Stem Cell Treatments in the World
      • 6.6.1.2. Hearticellgram-AMI Sales Estimates 2012-2014
      • 6.6.1.3. Will Have Difficulty Getting Approved in Markets Outside of South Korea
      • 6.6.1.4. Hearticellgram-AMI Revenue Forecast 2015-2026
    • 6.6.2. CardioRel (Reliance Life Sciences)
      • 6.6.2.1. Available on the Indian Market, but Does Data Back it up?
      • 6.6.2.2. CardioRel Revenue Forecast 2015-2026
  • 6.7. Stem Cell Cardiovascular Therapeutics Pipeline
    • 6.7.1. Ixmyelocel-T (Vericel Corporation)
      • 6.7.1.1. Vericel Shifts Focus Away from CLI and Towards DCM
      • 6.7.1.2. Currently in Phase 2b, with a Possible Launch in 2019
    • 6.7.2. Alecmestencel-T (Apceth)
    • 6.7.3. Arteriocyte: Using its ‘Magellan System' to Treat CLI
    • 6.7.4. MultiStem (Athersys) for Myocardial Infarction and Stroke
      • 6.7.4.1. Updates from Athersys Regarding Trial Status: Did MultiStem Fail in Stroke, or was it just Being Assessed in the Wrong Treatment Window?
    • 6.7.5. Baxter: Phase 3 CD34+ Stem Cell Therapy for Refractory Angina
    • 6.7.6. CardiAMP (BioCardia) for Heart Failure: Scheduled to Finally Begin Phase 3 in January 2016
    • 6.7.7. MyoCell (U.S. Stem Cell, Inc. - Formerly Bioheart): Autologous ‘Muscle Stem Cell' Therapy
      • 6.7.7.1. MyoCell: Is the Company Still Trying to Secure Funds to Restart the Phase 2/3 MARVEL Trial?
      • 6.7.7.2. MyoCell: MIRROR Trial on Hold
      • 6.7.7.3. MyoCell SDF-1: Improved Version of MyoCell
      • 6.7.7.4. MyoCell SDF-1 Phase 1 Trial (Regen): Another Trial Put on Hold
    • 6.7.8. CAP-1001 and CAP-1002 (Carpricor): Cardiospehere-Derived Cells for Heart Repair
    • 6.7.9. Ceylad (Formerly Cardio3): Proprietary Cardiopoiesis Technology Platform - Can be Applied to Various Stem Cell Sources
      • 6.7.9.1. C-Cure: Stem Cell Therapy for the Treatment of Heart Failure
      • 6.7.9.2. C-Cure: Two Phase 3 Trials Under Way
    • 6.7.10. Mesoblast: Mesenchymal Precursor Cells for Heart Failure and Myocardial Infarction
      • 6.7.10.1. CEP-41750: Phase 3 for Congestive Heart Failure (CHF), Chief Executive Provides Update
      • 6.7.10.2. CEP-41750: Promising Phase 2 Results, More Effective in a Particular Subset of Heart Failure Patients?
      • 6.7.10.3. Phase 2 Trial of MPCs in Acute Myocardial Infarction
    • 6.7.11. Caladrius Biosciences: Will not Continue Development of CLBS10, the Company's Former Lead Candidate
      • 6.7.11.1. CLBS12 for CLI: Due to Start Phase 2 in Japan in January 2016
    • 6.7.12. Stemedica Cell Technologies: ‘Ischaemic-Tolerant' Stem Cell Platform
      • 6.7.12.1. Trials in Myocardial Infarction and Stroke
    • 6.7.13. Gemacell and Cryocell (Human Stem Cells Institute): Awaiting Important Russian Legislation to be Passed Before Development can Continue
  • 6.8. Stem Cell Cardiovascular Therapeutics: Drivers and Restraints 2015-2026

7. Stem Cell Central Nervous System Therapeutics Segment 2015-2026

  • 7.1. Stem Cell Central Nervous System Therapeutics: Overview and Current Status
  • 7.2. Stem Cell Central Nervous System Therapeutics: Market Forecast 2015-2026
  • 7.3. The State of Stem Cell Research in CNS Diseases
    • 7.3.1. Stem Cells are the Best Hope for Many Serious CNS Conditions
    • 7.3.2. Awaiting a First Breakthrough Approval
    • 7.3.3. Human Neural Stem Cells (NSCs) Successfully Isolated
    • 7.3.4. NSCs Reach the Clinic Without Serious Controversy
    • 7.3.5. CNS Disorders are a Major Focus for ESC Research
    • 7.3.6. MSCs: Can Glial Cell and Astrocyte Formation Help Neurological Conditions?
  • 7.4. Progress in Specific CNS Conditions
    • 7.4.1. HSCT in MS: Could ‘Resetting' the Immune System Treat MS?
      • 7.4.1.1. Clinical Trials Involving HSCT in MS
      • 7.4.1.2. Barriers to Overcome Before HSCT Could Become an Established Therapy for MS
    • 7.4.2. ALS: Could this Rare Disease be the First Neurodegenerative Condition for Stem Cell Treatment?
    • 7.4.3. Parkinson's Disease: Field Recovering after Voluntary Moratorium on Stem Cell Research by Many Western Nations Ends
    • 7.4.4. Dry Age-Related Macular Degeneration: A Major Unmet Need
  • 7.5. Several Multi-Billion Dollar Markets are Open to Stem Cell Developers if they can Translate the Potential of Stem Cells into Therapies
  • 7.6. Stem Cell Central Nervous System Therapeutics Pipeline
    • 7.6.1. MA09-hRPE (Ocata Therapeutics): Stem Cells for Eye Diseases
      • 7.6.1.1. Orphan Drug Status in both the US and EU
      • 7.6.1.2. Current Clinical Trials in SMD
      • 7.6.1.3. Early Signs of Efficacy
      • 7.6.1.4. Has Moved into Phase 2 in AMD
    • 7.6.2. NurOwn (BrainStorm Cell Therapeutics): Neurotrophic Factor - Releasing Stem Cells for ALS
      • 7.6.2.1. Phase 2 Trial in 48 ALS Patients Underway
      • 7.6.2.2. Phase 2a Results Demonstrate “Statistically Significant Effect”
    • 7.6.3. International Stem Cell Corporation: Company Signals Intent to Start Phase 1/2a Study in PD Soon
    • 7.6.4. Neuralstem: Allogeneic NSCs for Synaptic Repair and Neuroprotection
      • 7.6.4.1. NSI-566 in ALS
      • 7.6.4.2. NSI-566 in ALS: Encouraging Data from Completed Phase 2 Trial
      • 7.6.4.3. NSI-566 for Chronic Spinal Cord Injury: Phase 1 Top-Line Data Expected Q4 2015
      • 7.6.4.4. NSI-566 for Ischaemic Stroke: Phase 1/2 Trials Underway in China
      • 7.6.4.5. Preclinical Investigation in 11 Other Indications
    • 7.6.5. PF-05206388 (Pfizer and the London Project to Cure Blindness): Finally Begins Phase 1Trial, with first Successful Surgery
    • 7.6.6. Q-Cells (Q Therapeutics): Phase 1/2 Trial Begins
    • 7.6.7. ReNeuron: CTX Neural Cell Line and its Advantages
      • 7.6.7.1. CTX for Stroke
      • 7.6.7.2. CTX for Stroke: Long-Term PISCES Study Shows Promising Results
      • 7.6.7.3. CTX for Stroke: Undergoing Phase 2, Using Highest Cell Dose from PISCES Study
    • 7.6.8. SB623 (SanBio): Enters Phase 2 for Stroke, as well as for Traumatic Brain Injury
    • 7.6.9. StemCells, Inc: A Leader in Neural Stem Cells
      • 7.6.9.1. HuCNS-SC for Pelizaeus-Merzbacher Disease: Undergoing Second Phase 1 Trial
      • 7.6.9.2. HuCNS-SC for NCL: Second Phase 1 Trial Withdrawn
      • 7.6.9.3. HuCNS-SC for Spinal Cord Injury: Phase 2
      • 7.6.9.4. HuCNS-SC for AMD: Top-Line Phase 1/2 Results Released
  • 7.7. Stem Cell Central Nervous System Therapeutics: Drivers and Restraints 2015-2026

8. Stem Cell Therapeutics in Other Disease Areas 2015-2026

  • 8.1. Stem Cell Therapeutics in Other Disease Areas: Overview and Current Status
  • 8.2. Stem Cell Therapeutics in Other Disease Areas: Market Forecast 2015-2026
  • 8.3. Stem Cell Therapeutics in Other Disease Areas: Therapies on the Market
    • 8.3.1. Osteocel Plus (NuVasive)
      • 8.3.1.1. Osteocel to Osteocel Plus: Passing Through Different Companies and Patent Disputes
      • 8.3.1.2. The Leading Stem Cell Orthobiologic
      • 8.3.1.3. Is it Better than Autograft?
      • 8.3.1.4. Osteocel Plus Revenue Forecast 2015-2026
    • 8.3.2. Trinity Evolution and Trinity Elite (Orthofix): Stem Cell Orthobiologics
      • 8.3.2.1. Positive Results from New Trial in Foot and Ankle Procedures
      • 8.3.2.2. Trinity Evolution and Elite Revenue 2010-2014
      • 8.3.2.3. Trinity Evolution and Elite Revenue Forecast 2015-2026
    • 8.3.3. CARTISTEM (MEDIPOST)
      • 8.3.3.1. CARTISTEM: The World's First Allogeneic Stem Cell Drug
      • 8.3.3.2. CARTISTEM: Latest Updates Includes Results from Phase 3 Trial, Initiation of Phase 1/2 Trial in the US
      • 8.3.3.3. CARTISTEM: Revenues 2013 - H1 2015
      • 8.3.3.4. CARTISTEM Revenue Forecast 2015-2026
    • 8.3.4. Allostem (Allosource)
    • 8.3.5. Map3 (RTI Surgical)
    • 8.3.6. ReliNethra for Ocular Surface Damage (Reliance Life Sciences)
    • 8.3.7. Cupistem (Anterogen)
  • 8.4. Stem Cell Therapeutics for Other Diseases: Research Areas
    • 8.4.1. HSCT for Orphan Diseases
    • 8.4.2. Potential for Genetically Modified Stem Cells for HIV and Other Diseases?
    • 8.4.3. Stem Cells Contribute to the Osteogenesis Process in Bone Repair
    • 8.4.4. Stem Cells Gaining Increasing Importance in Bone Graft Market, but whether these are True ‘Stem Cell Products' is Debatable
    • 8.4.5. Stem Cells also have Potential in Autoimmune Disorders
    • 8.4.6. Potential Cure for Diabetes?
  • 8.4.6.1. Clinical Stage Programmes in Diabetes
    • 8.4.7. Stem Cells in Active Liver Repair
    • 8.4.8. Long-Term Possibilities
  • 8.5. Stem Cell Therapeutics in Other Disease Areas: Pipeline
    • 8.5.1. ALLO-ASC and ALLO-ASC-DFU (Anterogen)
    • 8.5.2. MultiStem (Athersys): Fails Phase 2 Ulcerative Colitis, Still Undergoing Phase 1 as Immunomodulation Therapy after Liver Transplantation
    • 8.5.3. BioTime: Multiple Subsidiaries Focused on Regenerative Medicine
      • 8.5.3.1. AST-OPC1 and AST-VAC2 (Asterias Biotherapeutics)
      • 8.5.3.2. OpRegen (Cell Cure Neurosciences)
      • 8.5.3.3. Other BioTime Subsidiaries Related to Stem Cells: OncoCyte, ReCyte, ESI Bio, LifeMap Sciences Etc.
    • 8.5.4. Calimmune: Dual Anti-HIV Gene Therapy via Stem Cells
    • 8.5.5. (PDA-001 and PDA-002) Celgene Corporation
    • 8.5.6. ReJoin (Cellular Biomedicine Group): Interim Results from the MSCs for Knee Osteoarthritis
    • 8.5.7. PNEUMOSTEM (MEDIPOST)
      • 8.5.7.1. NEUROSTEM (MEDIPOST): Undergoing Phase 1/2 Trial and Obtains Patents Around the Globe
    • 8.5.8. Translational Biosciences: Set Up for the Sole Purpose of Conduction Stem Cell Clinical Trials, Five Phase 1/2 Trials Ongoing
    • 8.5.9. Mesoblast: MPCs for Various Indications
      • 8.5.9.1. MPC-300-IV in Diabetes
      • 8.5.9.2. MPC-300-IV in Rheumatoid Arthritis
      • 8.5.9.3. MPC-06-ID in Chronic Back Pain, Enters Phase 3
    • 8.5.10. Pluristem Therapeutics: Uses PLX Cells to Secrete Therapeutic Proteins in Damaged Tissues
      • 8.5.10.1. PLX-PAD: Phase 2 for Intermittent Claudication
      • 8.5.10.2. PLX-PAD: Completes Phase 1/2 for Injured Gluteal Muscle
      • 8.5.10.3. PLX-R18: In Preclinical Development for ARS
    • 8.5.11. Regeneus: Adipose Derived MSC Therapies
      • 8.5.11.1. Progenza Undergoing Phase 1 Trial
    • 8.5.12. S-Evans Biosciences: Menstrual Stem Cells
    • 8.5.13. TiGenix: Expanded Adipose-Derived Stem Cell Therapies
      • 8.5.13.1. EASC Technology Platform
      • 8.5.13.2. Cx601: Meets Primary Endpoint in Phase 3 Trial
      • 8.5.13.3. The Road to Approval for Cx601 in Europe and the US
      • 8.5.13.4. Cx611 for Rheumatoid Arthritis and also Severe Sepsis
      • 8.5.13.5. Cx621 - Positive Results from Phase 1 Trial, but Development on Hold
      • 8.5.13.6. ChondroCelect Already on the Market - Although is More of a Cell Therapy Rather than a Stem Cell Therapy
    • 8.5.14. VC-01 (ViaCyte)
  • 8.6. Genetically Modified Stem Cell Therapies
    • 8.6.1. BluebirdBio: Gene-Modified HSCs for Orphan Diseases
    • 8.6.2. GSK: Stem Cell Gene Therapies for Rare Diseases, Including one which has been Submitted for Approval in Europe

9. Stem Cell Non-Therapeutic Applications 2015-2026

  • 9.1. Stem Cell Non-Therapeutic Applications: Overview and Current Status
  • 9.2. Stem Cell Non-Therapeutic Applications: Market Forecast 2015-2026
  • 9.3. Stem Cell Banking: Growing Demand Worldwide
    • 9.3.1. Is there a Need for Stem Cell Banking as a Form of ‘Health Insurance'?
    • 9.3.2. Stem Cell Banking Companies in the US and Around the World
    • 9.3.3. Dental Stem Cell Banking: An Alternative to Cord Blood Banks?
  • 9.4. Stem Cell Supply and Processing: iPSCs are the New Driver
    • 9.4.1. Stem Cell Supply and Processing Companies
  • 9.5. Stem Cell-Based Assays: Major Potential for Preclinical Screens
    • 9.5.1. Advantages of Stem Cell-Based Assays
    • 9.5.2. Stem Cell-Based Assay Companies
  • 9.6. Research, Reagents, and Other Non-Therapeutic Stem Cell Activities
  • 9.7. Drivers and Restraints

10. Qualitative Analysis of the Stem Cell Technologies and Applications Market 2015-2026

  • 10.1. SWOT Analysis of the Stem Cell Technologies and Applications Market
  • 10.2. Strengths
    • 10.2.1. HSCT is Already an Established Procedure
    • 10.2.2. Approvals for Stem Cell Therapies
    • 10.2.3. Relaxation of Regulatory Barriers
  • 10.3. Weaknesses
    • 10.3.1. Uncertain Mechanisms of Action in Stem Cell Therapies
    • 10.3.2. Phase 3 Trials only make up a Small Fraction of the Currently Ongoing Clinical Trials
    • 10.3.3. Regulatory and Reimbursement Concerns
  • 10.4. Opportunities
    • 10.4.1. Huge Potential in Unmet Clinical Needs
    • 10.4.2. Opportunities in the Non-Therapeutic Uses of Stem Cells, including Cord Blood Banking and Cell-Based Assays
    • 10.4.3. Interactions with Related Technologies will Offer new Opportunities
    • 10.4.4. Genetic Modification of Stem Cells
  • 10.5. Threats
    • 10.5.1. Financial Risks and Under-Capitalisation of the Stem Cells Sector
    • 10.5.2. Threat of Pipeline Failures
    • 10.5.3. Long-Term Safety Concerns
  • 10.6. STEP Analysis of the Stem Cell Technologies and Applications Market
  • 10.7. Social Factors
    • 10.7.1. Increasing Burden of Disease as World Population Ages
    • 10.7.2. Biological Insurance Through Stem Cell Banking
    • 10.7.3. Stem Cell Tourism: Both an Opportunity and Threat to the Market
  • 10.8. Technological Factors
    • 10.8.1. Increasing Research Output
    • 10.8.2. IPSC Advances
    • 10.8.3. Greater Understanding of Stem Cell Differentiation
    • 10.8.4. Interactions with Other Technologies
    • 10.8.5. CRISPR: A Breakthrough in Genome Editing
  • 10.9. Economic Factors
    • 10.9.1. Grey Market for Stem Cell Therapies
    • 10.9.2. Broad Changes in Pharma / Healthcare Markets
    • 10.9.3. New Business Models are Required due to the Unique Challenges Posed by these Non-Traditional Therapies
  • 10.10. Political Factors
    • 10.10.1. Controversies over Embryonic Stem Cell Research
    • 10.10.2. Support from National Governments
    • 10.10.3. Patient Pressure to Deregulate the Stem Cell Therapies Market

11. Research Interviews

  • 11.1. Interview with Dr. Artur Isaev, General Director of Human Stem Cells Institute (HSCI)
    • 11.1.1. On the Skepticism Surrounding Cord Blood Banking
    • 11.1.2. Waiting on Russian Government to Introduce Important Legislation
    • 11.1.3. Current Strengths and Weaknesses of the Stem Cell Therapy Market
    • 11.1.4. On Competition Within the Market
    • 11.1.5. Future Prospects for Cord Blood Stem Cell Banking
    • 11.1.6. How Often are Stored Cells Used?
    • 11.1.7. Increasing Stem Cell Banking Services
    • 11.1.8. Progress with Gemacell and Cryocell
    • 11.1.9. Opportunities in Russia and Other Markets
    • 11.1.10. Challenges for Stem Cell Companies Over the Next Ten Years
    • 11.1.11. Developing the Stem Cell Therapy Market
  • 11.2. Interview with Dr. Stefanos Theoharis, Chief Business Officer at Apceth
    • 11.2.1. Latest Developments in the Market
    • 11.2.2. Latest Developments at Apceth
    • 11.2.3. Big Pharma, and General Public, Attitudes Towards Stem Cells
    • 11.2.4. Apceth's Aims over the Next Ten Years
    • 11.2.5. Strengths, Opportunities and Challenges
    • 11.2.6. Competition within the Stem Cell Market
    • 11.2.7. Differences between Regions with Regards to Stem Cells
    • 11.2.8. How the Stem Cell Industry Needs to Improve over the next Ten Years
  • 11.3. Interview with MEDIPOST
    • 11.3.1. Status of CARTISTEM Expansion Outside South Korea
    • 11.3.2. The Latest Developments in the Market and in the Company
    • 11.3.3. Drivers and Restraints in the Market, and Big Pharma's Attitudes Towards Stem Cells
    • 11.3.4. Milestones over the next Five Years
    • 11.3.5. Strengths
    • 11.3.6. Opportunities and Challenges
    • 11.3.7. Product Pipeline
    • 11.3.8. Competition in the Stem Cell Therapy Market
    • 11.3.9. Market Differences between South Korea and the Rest of the World
  • 11.4. Interview with Mr. Brock Reeve, Executive Director of Harvard Stem Cells Institute
    • 11.4.1. Recent Developments in Stem Cells
    • 11.4.2. Most Promising Techniques Over the Next Ten Years
    • 11.4.3. Interaction Between Gene Therapy and Stem Cells
    • 11.4.4. The Therapeutic Areas which will Benefit Most from Stem Cell Therapies
    • 11.4.5. The Need for New Business Models for Stem Cell Therapies?
    • 11.4.6. Steps Needed by Governments and Regulators
    • 11.4.7. Other Trends and Developments
  • 11.5. Interview with Dr. Leonard Zon, Director of the Stem Cell Programme at Boston's Children's Hospital
    • 11.5.1. Recent Developments in Stem Cells
    • 11.5.2. Research at Zon Laboratory
    • 11.5.3. Most Promising Techniques Over the Next Ten Years
    • 11.5.4. The Need for New Business Models?
    • 11.5.5. Developing the Market
    • 11.5.6. Other Trends and Developments

12. Conclusions

  • 12.1. Stem Cell Technologies and Applications: An Emerging Market
  • 12.2. Current Leading Segments and Regional Markets
  • 12.3. World Stem cell Technologies and Applications Market Forecast 2015-2026
  • 12.4. The Future of the Stem Cell Market
    • 12.4.1. Concluding Remarks

List of Tables

  • Table 2.1: Classifying Stem Cells by Potency
  • Table 2.2: The Different Germ Layers and Their Associated Types of Cells and Organs
  • Table 2.3: Main Types of Stem Cells and Their Properties
  • Table 2.4: Stem Cell Donor Terminology
  • Table 2.5: The Different Phases of Clinical Trials
  • Table 3.1: NIH Embryonic Stem Cell Registry: Stem Cell Lines by Status, 2014 and 2015
  • Table 3.2: New FDA Draft Guidances, 2014
  • Table 3.3: StemGen's Classifications of European Nations by Level of Permissiveness towards hESC research
  • Table 4.1: Stem Cell Technologies and Applications Market by Region: Revenues ($m), Market Shares (%), 2014
  • Table 4.2: Stem Cell Technologies and Applications Market by Segment: Revenues ($m), Market Shares (%), 2014
  • Table 4.3: Stem Cell Technologies and Applications Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2014-2020
  • Table 4.4: Stem Cell Technologies and Applications Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2021-2026
  • Table 4.5: Stem Cell Technologies and Applications Market Forecast by Segment: Revenues ($m), AGR (%), CAGR (%), 2014-2020
  • Table 4.6: Stem Cell Technologies and Applications Market Forecast by Segment: Revenues ($m), AGR (%), CAGR (%), 2021-2026
  • Table 4.7: Stem Cell Technologies and Applications Market by Segment: Revenues ($m), Market Share (%), 2020 and 2026
  • Table 5.1: Stem Cell Cancer Therapeutics Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2014-2020
  • Table 5.2: Stem Cell Cancer Therapeutics Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2021-2026
  • Table 5.3: Comparison of Bone Marrow, Peripheral Blood and Cord Blood for HSCT
  • Table 5.4: Estimated Number of HSCT Operations Performed Globally, by Donor Type: AGR (%), CAGR (%), 2012-2014
  • Table 5.5: European HSCT Operations: Number of Operations by Donor Type, 2003-2012
  • Table 5.6: Indications with Medicare Coverage for HSCT (both Autologous and Allogeneic)
  • Table 5.7: Malignancies and Other Haematological Diseases which may be Treated with HSCT
  • Table 5.8: HSCT-Addressable Cancers: Estimated Combined Incidence in the US, Japan and Western Europe (Number of Cases), CAGR (%), 2012-2024
  • Table 5.9: FDA-Approved Cord Blood-Derived Stem Cell Products for HSCT, 2015
  • Table 5.10: Past and Present ProHema (Fate Therapeutics) Clinical Trials, 2015
  • Table 5.11: MSC-100-IV / Temcell HS Forecast (Mesoblast / JCR Pharmaceuticals): Revenues ($m), AGR (%), CAGR (%), 2014-2020
  • Table 5.12: MSC-100-IV / Temcell HS Forecast (Mesoblast / JCR Pharmaceuticals): Revenues ($m), AGR (%), CAGR (%), 2021-2026
  • Table 5.13: HSC835 (Novartis) Ongoing Clinical Trials, 2015
  • Table 6.1: Stem Cell Cardiovascular Therapeutics Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2014-2020
  • Table 6.2: Stem Cell Cardiovascular Therapeutics Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2021-2026
  • Table 6.3: Global Cardiovascular Disease Market by Drug Class: Revenue ($bn), 2014
  • Table 6.4: Projected Global Deaths from Ischaemic Heart Disease and Stroke (millions ), % of Total Deaths, Deaths Per 100,000 Population, 2015 and 2030
  • Table 6.5: Hearticellgram-AMI (Pharmicell) Sales Estimates: Revenue ($m), AGR (%), 2012-2014
  • Table 6.6: Hearticellgram-AMI Forecast (Pharmicell): Revenues ($m), AGR (%), CAGR (%), 2014-2020
  • Table 6.7: Hearticellgram-AMI Forecast (Pharmicell): Revenues ($m), AGR (%), CAGR (%), 2021-2026
  • Table 6.8: CardioRel (Reliance Life Sciences) Forecast: Revenues ($m), AGR (%), CAGR (%), 2014-2020
  • Table 6.9: CardioRel (Reliance Life Sciences) Forecast: Revenues ($m), AGR (%), CAGR (%), 2021-2026
  • Table 6.10: Past and Present MultiStem (Athersys) Clinical Trials, 2015
  • Table 6.11: Ongoing Stemedica Cell Technologies Clinical Trials in Cardiovascular Indications, 2015
  • Table 7.1: Stem Cell CNS Therapeutics Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2014-2020
  • Table 7.2: Stem Cell CNS Therapeutics Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2021-2026
  • Table 7.3: Ongoing MA09-hRPE (Ocata Therapeutics) Clinical Trials in SMD, 2015
  • Table 7.4: Ongoing MA09-hRPE (Ocata Therapeutics) Clinical Trials in AMD, 2015
  • Table 8.1: Stem Cell Therapeutics in Other Disease Areas Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2014-2020
  • Table 8.2: Stem Cell Therapeutics in Other Disease Areas Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2021-2026
  • Table 8.3: Osteocel Plus Forecast (NuVasive): Revenues ($m), AGR (%), CAGR (%), 2014-2020
  • Table 8.4: Osteocel Plus Forecast (NuVasive): Revenues ($m), AGR (%), CAGR (%), 2021-2026
  • Table 8.5: Trinity Evolution and Elite (Orthofix): Revenues ($m), AGR (%), CAGR (%), 2010-2014
  • Table 8.6: Trinity Evolution and Elite (Orthofix) Forecast: Revenues ($m), AGR (%), CAGR (%), 2014-2020
  • Table 8.7: Trinity Evolution and Elite (Orthofix) Forecast: Revenues ($m), AGR (%), CAGR (%), 2021-2026
  • Table 8.8: CARTISTEM Revenues: Revenue ($m), AGR (%), 2013-H1 2015
  • Table 8.9: CARTISTEM (MEDIPOST) Forecast: Revenues ($m), AGR (%), CAGR (%), 2014-2020
  • Table 8.10: CARTISTEM (MEDIPOST) Forecast: Revenues ($m), AGR (%), CAGR (%), 2021-2026
  • Table 8.11: Non-Oncologic Diseases which can be Treated with HSCT
  • Table 8.12: Processes and Mechanisms of Bone Repair
  • Table 8.13: Anterogen Clinical Trials, 2015
  • Table 8.14: PDA-002 (Celgene Corporation) Current Clinical Trials, 2015
  • Table 8.15: PNEUMOSTEM (MEDIPOST) Past and Present Clinical Trials, 2015
  • Table 8.16: Translational Biosciences Currently Open Clinical Trials, 2015
  • Table 8.17: S-Evans Biosciences Clinical Trials, 2015
  • Table 9.1: Stem Cell Non-Therapeutic Applications Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2014-2020
  • Table 9.2: Stem Cell Non-Therapeutic Applications Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2021-2026
  • Table 9.3: Select US Stem Cell Banks, 2015
  • Table 9.4: Select Non-US Stem Cell Banks, 2015
  • Table 9.5: Select Stem Cell Supply and Processing Companies, 2015
  • Table 9.6: Select Companies with Involvement in Stem Cell-Based Assays, 2015
  • Table 9.7: Select Companies with Involvement in Stem Cell-Based Assays, 2015
  • Table 10.1: World 65+ Population Forecast: Population (m), CAGR (%), 2015-2050

List of Figures

  • Figure 1.1: Global Stem Cell Technologies and Applications Market Segmentation Overview, 2015
  • Figure 2.1: Timeline of Stem Cell Research
  • Figure 3.1: NIH Embryonic Stem Cell Registry: Stem Cell Lines by Status, 2015
  • Figure 3.2: CIRM Funding by Disease Area, Percentage (%), 2015
  • Figure 4.1: Therapeutic Applications of Stem Cells vs Non-Therapeutic Applications: Market Shares (%), 2014
  • Figure 4.2: Therapeutic Applications of Stem Cells vs Non-Therapeutic Applications: Market Shares (%), 2026
  • Figure 4.3: Stem Cell Technologies and Applications Market by Region: Market Shares (%), 2014
  • Figure 4.4: Stem Cell Technologies and Applications Market by Segment: Market Shares (%), 2014
  • Figure 4.5: Stem Cell Technologies and Applications Market Forecast: Revenues ($m), 2014-2026
  • Figure 4.6: Stem Cell Technologies and Applications Market Forecast by Segment: Revenue ($m), 2014-2026
  • Figure 4.7: Stem Cell Technologies and Applications Market Forecasts by Segment, 2015-2026
  • Figure 4.8: Stem Cell Technologies and Applications Market: Market Shares (%) by Segment, 2020
  • Figure 4.9: Stem Cell Technologies and Applications Market: Market Shares (%) by Segment, 2026
  • Figure 4.10: Stem Cell Technologies and Applications Market: Drivers and Restraints, 2015-2026
  • Figure 5.1: Stem Cell Cancer Therapeutics Market Forecast: Revenue ($m), 2014-2026
  • Figure 5.2: Estimated Proportions of Global HSCT Operations by Donor Type, 2014
  • Figure 5.3: European HSCT Operations by Donor Type, 2003-2012
  • Figure 5.4: HSCT-Addressable Cancers: Estimated Combined Incidence in the US, Japan and Western Europe (Number of Cases), 2012-2024
  • Figure 5.5: Most Common Diseases Treated by Cord Blood from LifeCord: Percentage (%) 2015
  • Figure 5.6: MSC-100-IV / Temcell HS Forecast (Mesoblast / JCR Pharmaceuticals): Revenue ($m), 2014-2026
  • Figure 5.7: Stem Cell Cancer Therapeutics Market: Drivers and Restraints, 2015-2026
  • Figure 6.1: Stem Cell Cardiovascular Therapeutics Market Forecast: Revenue ($m), 2014-2026
  • Figure 6.2: Global Cardiovascular Disease Market by Drug Class: Market Shares (%), 2014
  • Figure 6.3: Projected Global Deaths from Ischaemic Heart Disease and Stroke (millions ), 2015 and 2030
  • Figure 6.4: Hearticellgram-AMI (Pharmicell) Sales Estimates: Revenue ($m), 2012-2014
  • Figure 6.5: Hearticellgram-AMI (Pharmicell) Forecast: Revenue ($m), 2014-2026
  • Figure 6.6: CardioRel (Reliance Life Sciences) Forecast: Revenue ($m), 2014-2026
  • Figure 6.7: Stem Cell Cardiovascular Therapeutics Market: Drivers and Restraints, 2015-2026
  • Figure 7.1: Stem Cell CNS Therapeutics Market Forecast: Revenue ($m), 2014-2026
  • Figure 7.2: Stem Cell CNS Therapeutics Market: Drivers and Restraints, 2015-2026
  • Figure 8.1: Stem Cell Therapeutics in Other Disease Areas Market Forecast: Revenues ($m), 2015-2026
  • Figure 8.2: Osteocel Plus (NuVasive) Forecast: Revenue ($m), 2014-2026
  • Figure 8.3: Trinity Evolution and Elite (Orthofix): Revenue ($m), 2010-2014
  • Figure 8.4: Trinity Evolution and Elite (Orthofix): Revenue ($m), 2014-2026
  • Figure 8.5: CARTISTEM (MEDIPOST) Forecast: Revenues ($m) 2014-2026
  • Figure 9.1: Stem Cell Non-Therapeutic Applications Market Forecast: Revenue ($m), 2014-2026
  • Figure 9.2: Stem Cell Non-Therapeutic Applications Market: Drivers and Restraints, 2015-2026
  • Figure 10.1: SWOT Analysis of the Stem Cell Technologies and Applications Market, 2015-2026
  • Figure 10.2: STEP Analysis of the Stem Cell Technologies and Applications Market 2015-2026
  • Figure 10.3: World 65+ Population Forecast: Population (m), 2015-2050
  • Figure 12.1: Stem Cell Technologies and Applications Market Forecast, split by Therapeutic vs Non-Therapeutic Applications: Revenue ($m), 2014-2026

Companies Listed

  • 3-D Matrix
  • Aastrom Biosciences
  • Adistem
  • Advanced Cell Technology
  • Alder Biopharmaceuticals
  • Alkems
  • AllCells
  • Allergan
  • AlloSource
  • American Academy of Neurology
  • American Academy of Pediatrics (AAP)
  • American Neurological Associates Annual Meeting
  • American Society of Blood and Marrow Transplantation.
  • Americas Committee for Treatment and Research in Multiple Sclerosis
  • Americord
  • Amgen
  • Angiocrine Bioscience
  • Anterogen
  • Antria
  • Apceth
  • Arteriocyte
  • Associated Press
  • Asterias Biotherapeutics
  • Athersys
  • Auriga Ventures
  • Axiogenesis
  • Baxter Healthcare
  • BaYi Brain Hospital
  • BioCardia
  • BioE
  • BioEden
  • Biogenea-Cellgenea
  • Bioheart, Inc
  • Biologic Therapies
  • Biomatrica
  • BioMet Orthopedics
  • Biotec Services International
  • BioTime
  • BioTime Asia
  • Blackstone Medical
  • Bluebird Bio
  • BMJ (The British Medical Journal)
  • Boston Children's Hospital
  • BrainStorm Cell Therapeutics
  • Caladrius Biosciences
  • California Institute for Regenerative Medicine (CIRM)
  • Calimmune
  • Capricor
  • Cardio3
  • Caribou
  • Carolinas Cord Blood Bank (CCBB)
  • Casey Eye Institute
  • Cedars-Sinai Heart Institute
  • Cell (journal)
  • Cell Cure Neurosciences
  • Cell Therapy Catapult
  • CellCentric
  • Cellectis
  • Cellerant Therapeutics
  • Cellerix
  • CELLTREE
  • Cellular Biomedicine Group (CBMG)
  • Cellular Dynamics International
  • Center for International Blood and Marrow Transplant Research (CIBMTR)
  • Centers for Medicare & Medicaid Services
  • Cephalon
  • Cesca Therapeutics
  • Ceylad
  • Cha General Hospital
  • China Cord Blood Corporation
  • China Food and Drug Administration (CFDA)
  • Chinese Academy of Sciences
  • Chinese Ministry of Health
  • Chinese Ministry of Science and Technology
  • CJ CheilJedang
  • Clal Biotechnologies Industries
  • Cleveland Biolabs
  • Clinicaltrials.gov
  • ClinImmune Labs
  • Cochrane
  • Cognate BioServices
  • Committee for Medicinal Products for Human Use (CHMP)
  • Consortium of Multiple Sclerosis Centers
  • Cook General BioTechnology
  • Cord Blood America
  • Cord Blood Registry Systems
  • Cordlife Group
  • CRISPR Therapeutics
  • Cryo-Cell International
  • CryoCord
  • Cryonix CJSC
  • Cryo-Save
  • CXR Biosciences
  • Cytori Therapeutics
  • Data Safety Monitoring Board (DSMB)
  • Denali Ventures
  • Dendreon
  • Dong-A Pharmaceuticals Co
  • Drugs and Cell Therapies in Haematology (Journal)
  • Duke University School of Medicine
  • Elbit Imaging
  • Elbit Medical Technologies
  • Eli Lilly
  • Elsevier
  • EMA
  • EMA Committee for Orphan Medicinal Products
  • EpiStem
  • ESI Bio
  • European Court of Human Rights
  • European Court of Justice
  • European Group for Blood and Marrow Transplantation (EBMT)
  • European Haematology Association
  • EuroStemCell
  • Fate Therapeutics
  • FDS Pharma
  • Federal D.C. Court of Appeals
  • Fondazione Centro San Raffaele
  • Fondazione Telethon
  • Forbion Capital Partners
  • Forticell Bioscience
  • Gamida Cell
  • Gemabank
  • Gene Therapy Advisory Committee
  • Genetico
  • Genetrix Group
  • Geron
  • Gilead
  • GlobalStem
  • Globocan
  • GSK
  • Harvard Apparatus Regenerative Technology
  • Harvard Business School
  • Harvard Stem Cell Institute
  • Harvard University
  • Howard Hughes Medical Institute
  • Human Fertilisation and Embryology Authority (HFEA)
  • Human Stem Cells Institute
  • Human Tissue Authority
  • ImmunoCellular Therapeutics
  • Immunovative Therapies
  • Indian Department of Biotechnology
  • Insception Biosciences
  • Intellia Therapeutics
  • IntelliCell Biosciences
  • International Society for Stem Cell Research (ISSCR)
  • International Stem Cell Corporation (ISCO)
  • International Stemcell Services
  • IPS Academia Japan
  • Isar Medical Centre
  • Israel Healthcare Venture
  • Israel Stem Cell Society
  • Japan Institute of Biomedical Research.
  • Japan's Ministry of Economy, Trade and Industry (METI)
  • Japanese Health Ministry
  • Japanese Ministry of Labour and Welfare (MHLW)
  • Japanese Pharmaceuticals and Medical Devices Agency
  • JCR Pharmaceuticals
  • JingYuan Bio
  • Johnson & Johnson
  • Karolinska Institute
  • Korean Food and Drug Administration
  • Korean MFDS (Ministry of Food and Drug Safety)
  • Lifebank Cryogenics
  • LifebankUSA
  • LifeMap Sciences
  • LifeMap Solutions
  • LifeSouth Community Blood Centers Inc
  • Lonza
  • Massachusetts General Hospital
  • Maxcyte
  • Mayo Clinic
  • McMaster University
  • MedCell Bioscience
  • MEDIPOST
  • Medistem Panama
  • Medtronic
  • Mesoblast
  • Miltenyi Biotec
  • Musculoskeletal Transplant Foundation (MTF)
  • National Dental Pulp Laboratory
  • Nature (journal)
  • Nature Biotechnology (Journal)
  • NeoStem
  • Neuralstem
  • New England Journal of Medicine
  • New York Blood Center
  • New York Blood Center's Milstein National Cord Blood Program (NCBP)
  • New York Heart Association
  • NHS Blood and Transplant Authority
  • Northwestern University
  • Novartis
  • Novartis Research Foundation
  • NurOwn
  • Nuvasive
  • Ocata Therapeutics
  • OncoCyte
  • Opexa Therapeutics
  • Oregon Health and Science University
  • OrLife Bio
  • Orthofix
  • Osiris Therapeutics
  • Pahrump Valley Times
  • Pfizer
  • Pharmicell
  • Pharmsynthez
  • Plasticell
  • Pluristem
  • Polyphor
  • Prix Galien
  • Q Therapeutics
  • Queen Mary University of London
  • Quest Biomedical
  • ReCyte
  • Regenerative Sciences
  • Regenerex
  • Regeneron
  • Regeneus
  • Reliance Group
  • Reliance Life Sciences
  • ReNeuron
  • RepliCel Life Sciences
  • Reprobank
  • ReproCELL
  • RIKEN Center for Developmental Biology
  • Roche
  • Roslin Cellab
  • RTI Biologics
  • RTI Surgical
  • RUSNANO Corporation
  • RVC OJSC
  • SanBio
  • Sangamo BioSciences
  • Sanofi
  • Science (journal)
  • S-Evans Biosciences
  • Spinesmith Partners
  • SSM Cardinal Glennon Children's Medical Center
  • Stem Cell Bank
  • Stemcell Technologies
  • StemCells
  • StemCore
  • StemCyte
  • Stemedica Cell Technologies
  • StemGen
  • Stemina Biomarker Discovery
  • SynBio
  • TAP Biosystems (Sartorius Stedim Biotech
  • Tel Aviv University
  • Teva
  • The Committee for Advanced Therapies (CAT)
  • The European Commission
  • The Lancet
  • The London Project to Cure Blindness
  • The Marcus Foundation
  • The Zon Laboratory
  • Therapeutic Goods Administration
  • TiGenix
  • Tong Yuan Stem Cell
  • TrakCel
  • Translational Biosciences
  • U.S. Stem Cell, Inc
  • UCL Business PLC
  • UCL Institute of Ophthalmology
  • UCLA
  • UK Care Quality Commission
  • UK Department of Health
  • UK Department of Health and the Medical Research Council
  • UK Home Office
  • UK Medicines and Healthcare Products Regulatory Agency (MHRA)
  • UK National Institute for Health Research
  • UK Regenerative Medicine Platform
  • uniQure
  • United Nation's Department of Economic and Social Affairs
  • University of California
  • University of Colorado Anschutz Medical Campus (AMC)
  • University of Colorado Cord Blood Bank
  • University of Kyoto
  • University of Massachusetts
  • University of Washington
  • University of Western Ontario
  • University of Wisconsin Alumni Research Foundation
  • US Congress
  • US District Court for the District of Columbia
  • US FDA
  • US National Cord Blood Program
  • US National Institute of Allergy and Infectious Diseases (NIAID)
  • US National Institute of Health (NIH)
  • US National Marrow Donor Program
  • US National Marrow Donor Program (NMDP)
  • US Patent and Trademark Office
  • US Supreme Court
  • Valeant
  • Vericel Corporation
  • Vesta Therapeutics
  • ViaCord
  • ViaCyte
  • ViroMed
  • Vitro Biopharma
  • WA Optimum Health Care
  • WHO
  • Yale University
Back to Top